Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Olaparib after surgery resulted in durable response rates in patients with high-risk biochemically recurrent prostate cancer ...

The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics. Each of their ...

AstraZeneca has been boosted by results from ASCO which show its Lynparza could expand its use beyond ovarian cancer. Results from a phase 3 trial presented today showed that patients treated with ...

AstraZeneca and partner Merck & Co look set to have a much narrower label for their PARP inhibitor Lynparza in prostate cancer than they were hoping for in the US. The FDA’s Oncologic Drugs ...

The MEDIOLA trial evaluated olaparib (Lynparza) and durvalumab (Imfinzi) with or without bevacizumab in recurrent ovarian cancer and showed a 34% response rate with the PARP inhibitor and the PD-L1 ...

Patients with platinum-sensitive relapsed ovarian cancer given maintenance olaparib/cediranib had similar progression-free ...

PARP inhibitor Lynparza (olaparib) is a targeted treatment option that has been studied in early and metastatic breast cancer patients with an inherited BRCA mutation. AstraZeneca with MSD (Merck & Co ...

In March, the company reported that a late-stage study evaluating the combination of Keytruda and Lynparza in metastatic non-squamous NSCLC indication failed to meet its primary endpoints.

In recent months, the Keytruda-Astraeneca Lynparza combination and Keytruda with Eisai's Lenvima also failed separate trials as cancer treatments. Keytruda belongs to a class of medicines called ...

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that an ...